Could a Half-Matched donor cure a rare immune disease?

NCT ID NCT03910452

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive chemotherapy, radiation, and immune-suppressing drugs before and after the transplant to help their body accept the new cells. The goal is to see if the transplant can restore normal immune function without causing severe graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bone marrow transplant from a partially matched relative, with chemotherapy (busulfan), immune-suppressing drug (alemtuzumab), radiation, and post-transplant cyclophosphamide

What this could lead to

If it works, this could offer a cure for people with chronic granulomatous disease who don't have a perfectly matched donor.

What could go wrong

This is a very early, small trial (only 4 people) testing a high-risk procedure. The transplant may fail, cause severe graft-versus-host disease, or lead to serious infections or other complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic granulomatous disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States